Pramodini Medicare IPO Allotment Status 18 August 2026: What Investors Need to Track

Pramodini Medicare IPO is drawing attention from retail and HNI investors on 18 August 2026 as the issue enters its subscription window. The Pramodini Medicare IPO covers the Healthcare and Pharmaceuticals sector, and the company is seeking to raise capital through a public listing on the SME segment of the stock exchange. Subscription has closed; allotment is expected shortly. Pramodini Medicare is engaged in the healthcare and pharmaceuticals sector, potentially covering medical devices, pharmaceutical products, or healthcare services. The company sought capital through its SME IPO to expand operations, strengthen its product portfolio, or fund general corporate purposes as detailed in its RHP.

SME IPOs offer investors an opportunity to participate in the early-stage growth of smaller listed companies, but they also carry a distinct risk profile compared to mainboard IPOs. The this IPO is being closely watched by investors interested in the Healthcare and Pharmaceuticals space. Allotment date to be announced by the registrar. All subscription details including the price band, lot size, and issue size are available in the company's SEBI-approved Red Herring Prospectus (RHP), which can be accessed through the NSE or BSE website and the registrar's platform.

Click Here – Get Free Investment Predictions

About Pramodini Medicare and the Healthcare and Pharmaceuticals Sector

Pramodini Medicare is engaged in the healthcare and pharmaceuticals sector, potentially covering medical devices, pharmaceutical products, or healthcare services. The company sought capital through its SME IPO to expand operations, strengthen its product portfolio, or fund general corporate purposes as detailed in its RHP. The Healthcare and Pharmaceuticals sector in India has seen growing investor interest in recent years, as companies in this space seek to list on SME exchanges to access public capital for expansion. The Pramodini Medicare IPO is part of this broader trend of SME companies tapping the capital markets to fund growth plans, working capital requirements, or general corporate purposes.

India's SME exchange ecosystem, comprising NSE Emerge and BSE SME, has grown substantially in the past several years, with hundreds of companies having listed successfully. SME IPOs are accessible to retail investors with a minimum application amount as specified in the RHP, and they follow a book-building or fixed-price mechanism. Investors considering this IPO should read the RHP carefully for the company's business model, financials, and risk factors before applying.

Pramodini Medicare IPO Subscription Details

Parameter	Details
Company Name	Pramodini Medicare
Sector	Healthcare and Pharmaceuticals
Subscription Dates	12-14 August 2026
Issue Type	SME IPO
Price Band	Refer to the SEBI-approved RHP and BSE/NSE official data
Lot Size	Refer to the SEBI-approved RHP and BSE/NSE official data
Issue Size	Refer to the SEBI-approved RHP and BSE/NSE official data
Allotment Date	Refer to BSE/NSE corporate action announcements
Listing Date	Refer to BSE/NSE corporate action announcements

All financial figures are to be verified from the company's SEBI-approved RHP and official NSE/BSE disclosures. This article does not reproduce or confirm specific financial data.

Pramodini Medicare IPO Allotment Status

The the subscription window ran from 12-14 August 2026 and has now closed. Eligible investors can apply for this IPO through their bank's ASBA (Application Supported by Blocked Amount) facility or through UPI-based bid submission via the NSE or BSE bidding platforms. Most brokerage apps, including Univest, allow retail investors to apply for IPOs directly through the app using their linked bank account and UPI ID.

To apply for the Pramodini Medicare IPO, ensure your Demat account is active and your UPI ID or bank account is registered with your broker. Enter the number of lots and the cut-off price in the bid form. The application amount will be blocked in your bank account until allotment. If allotted, the blocked amount is debited; if not allotted, the block is released. For category-specific eligibility and cut-off price rules, refer to the Pramodini Medicare RHP.

Research Pramodini Medicare and Compare SME IPOs on the Univest Screener

Pramodini Medicare IPO Grey Market Premium

Univest does not publish grey market premium figures for any IPO. The grey market premium for this IPO, like all grey market data, is collected informally outside regulated stock exchanges and is not verified, endorsed, or published by SEBI, NSE, or BSE. Grey market premium figures can vary significantly between trackers and are not always accurate. For grey market data, visit established GMP tracking websites and treat any figures as informal indicators only, not as forecasts of listing price or returns.

Risks of Investing in Pramodini Medicare IPO

All equity investments carry risk, and SME IPOs carry specific risks that investors must consider before applying for this IPO. Lower liquidity in the secondary market after listing, limited track record for smaller companies, concentration in a single sector or geography, and the potential for pricing above intrinsic value in a bull market are all factors to weigh. The following risks are specific to the Healthcare and Pharmaceuticals sector and this IPO.

Pharmaceutical Regulatory Risk

Healthcare and pharma companies are subject to stringent regulatory oversight from CDSCO and state drug authorities. Any regulatory non-compliance, product recall, or failure to obtain required approvals can significantly impact the business of Pramodini Medicare.

Competition in Healthcare and Pharma

The Indian pharmaceutical and healthcare sector is highly competitive, with numerous domestic manufacturers, generic producers, and multinational companies operating across segments. Smaller companies like those seeking SME IPO listing must differentiate on product quality, pricing, or niche positioning.

Working Capital Intensity in Pharma

Pharmaceutical manufacturing and distribution typically requires significant working capital for raw material procurement, manufacturing, quality testing, and distribution channel management. Cash flow management is a key risk for investors in this issue to assess.

Download the Univest iOS App or Univest Android App to track the the allotment status and stay updated on SME IPO listings.

Conclusion

The Pramodini Medicare IPO is subscription has closed; allotment is expected shortly, with the subscription window running from 12-14 August 2026. Investors interested in the Healthcare and Pharmaceuticals sector and in SME IPO opportunities should read the company's SEBI-approved RHP thoroughly, check the price band and lot size from official exchange sources, and apply through the ASBA or UPI mechanism before the close of the subscription window. This IPO should be evaluated on its business fundamentals, valuation relative to peers, and your own risk tolerance. Consult a SEBI-registered financial advisor before making any investment decision based on an IPO subscription.

Frequently Asked Questions on Pramodini Medicare IPO

Has Pramodini Medicare IPO subscription closed?

Ans. Yes, Pramodini Medicare IPO subscription closed on 14 August 2026 after a three-day window from 12 to 14 August. No further bids can be placed. The issue is in the allotment phase, with allotment results expected to be declared within a few business days of the subscription closing date.

When is Pramodini Medicare IPO allotment?

Ans. Pramodini Medicare IPO allotment is expected within a few business days of the subscription closing on 14 August 2026. The registrar will publish the allotment date on their website. Check allotment status using your PAN or application number on the registrar's portal or BSE's allotment page.

How to check Pramodini Medicare IPO allotment status?

Ans. Check Pramodini Medicare IPO allotment status on the registrar's website using your PAN, application number, or Demat account information. You can also use BSE's official IPO allotment portal at bseindia.com. The registrar details for these IPO shares are published in the company's RHP and on exchange disclosures.

What does Pramodini Medicare do?

Ans. Pramodini Medicare operates in the healthcare and pharmaceutical sector. For complete details on the company's products, revenue, profitability, regulatory approvals, and business model, refer to the SEBI-approved Red Herring Prospectus for the Pramodini Medicare IPO, accessible through NSE or BSE.

When will Pramodini Medicare IPO list?

Ans. the SME IPO listing is expected within 6 to 8 business days of the subscription closing on 14 August 2026. The exact listing date will be officially announced by the company and the registrar. Monitor NSE and BSE corporate action announcements for the confirmed listing date.

What is the GMP of this IPO?

Ans. Univest does not publish grey market premium figures for Pramodini Medicare IPO. GMP is an unofficial, unregulated indicator not endorsed by SEBI, NSE, or BSE. For grey market data, visit GMP tracking platforms and treat any figures as informal estimates rather than reliable forecasts of listing price or returns.

What are the risks of Pramodini Medicare as an investment?

Ans. Key risks include stringent pharmaceutical regulatory requirements, intense competition in the Indian pharma and healthcare market, working capital intensity, and the lower secondary market liquidity typical of SME IPO stocks. Read the full risk factors section in the the company's RHP before making any investment decision.